A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic Migraine

NCT ID: NCT02378844

Last Updated: 2019-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 477 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2018-08-29

Brief Summary

A prospective, double-blind, randomized, sham-controlled, multicentre investigation.

Detailed Description

The study period will begin with a four week run-in period, during which there is no investigational treatment. The purpose of the run-in period will be observation for baseline comparison.

The run-in period will be, followed by a 12 week randomized period when the subjects will be randomized (1:1) to either active treatment or sham (inactive) treatment.

The randomized period will be followed by a 24 week open label period, where the subjects in the sham treatment group will switch in treatment assignment and receive a gammaCore®-R and the gammaCore®-R will continue to receive an active treatment.

Conditions

Migraine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

gammaCore®-R

Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

Group Type: ACTIVE_COMPARATOR

gammaCore®-R

Intervention Type: DEVICE

Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

gammaCore®-R Sham

Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

Group Type: SHAM_COMPARATOR

gammaCore®-R Sham

Intervention Type: DEVICE

Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

Interventions

gammaCore®-R

Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

Intervention Type: DEVICE

gammaCore®-R Sham

Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Is between the ages of 18 and 75 years.

2. Has been previously diagnosed with migraine (with or without aura) in accordance with the International Classification of Headache Disorders (ICHD)-3 Beta Classification criteria.

3. Experience between 5 and 12 migraine days per month (over the last 4 months) with at least 2 of the migraines lasting more than 4 hours.

4. Has age of onset of migraine less than 50 years old.

5. Agrees not to use any migraine prevention treatments (including Botox injections) and/or medications (exclusive of medications taken for acute relief of migraine symptoms).

6. Agrees to refrain from initiating or changing the type, dosage or frequency of any prophylactic medications for indications other than migraine that in the opinion of the clinician may interfere with the study objectives (e.g. antidepressant, anti convulsant, beta blockers, etc.).

7. Agrees to use the gammaCore®-R device as intended, follow all of the requirements of the study including follow-up visit requirements, record required study data in the subject dairy, and other self-assessment questionnaires.

8. Is able to provide written Informed Consent.

Exclusion Criteria

1. Has a concomitant medical condition that will require oral or injectable steroids during the study.

2. Has a history of any intracranial aneurysm, intracranial haemorrhage, brain tumour or significant head trauma.

3. Has a structural abnormality at the gammaCore®-R treatment site (e.g lymphadenopathy previous surgery or abnormal anatomy).

4. Has pain at the gammaCore®-R treatment site (e.g.dysesthesia, neuralgia and/or cervicalgia).

5. Has other significant pain problem (e.g.cancer pain, fibromyalgia or other head or facial disorder) that in the opinion of the investigator may confound the study assessments

6. Has know or suspected severe cardiac disease(e.g. symptomatic coronary artery disease, prior myocardial infarction, congestive heart failure (CHF)).

7. Has known or suspected severe cerebrovascular disease, (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior carotid endarterectomy or other vascular neck surgery).

8. Has an abnormal baseline Electrocardiogram (ECG) e.g. second and third degree heart block, prolonged QT interval, atrial fibrillation, atrial flutter, history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction).

9. Has had a cervical vagotomy.

10. Has uncontrolled high blood pressure (systolic >160 diastolic > 100 after 3 repeated measurements within 24 hours).

11. Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator).

12. Has been implanted with metal cervical spine hardware or has a metallic implant near the gammaCore®-R stimulation site.

13. Has a known history of suspicion of secondary headache.

14. Has a history of syncope (within the last five years).

15. Has a history of seizures (within the last five years).

16. Has a known or suspicion of substance abuse or addiction (within the last 5 years).

17. Is using marijuana (including medical marijuana) for any indications, more than twice a month.

18. Currently takes simple analgesics or non-steroidal anti-inflammatory drugs (NSAIDs) greater than 15 days per month or triptans, ergots or combined analgesics greater than 10 days per month for headaches or other body pain.

19. Currently takes prescription opioids greater than 2 days per month for headaches or body pain.

20. Has taken medications for migraine prophylaxis in the previous 30 days.

21. Has previous diagnosis of medication overuse headache (MoH) , which has reverted to episodic migraine within the last 6 months.

22. Meets the ICHD-3 Beta Classification criteria for chronic migraine (> 15 headache days per month).

23. Has failed an adequate trial (two months or greater) of at least 3 classes of a drug therapy for the prophylaxis of migraine .

24. Has had surgery for migraine prevention.

25. Has undergone nerve block (occipital or other) in the head or neck within the last 2 months.

26. Has received Botox injections within the last 6 months.

27. Is pregnant or thinking of becoming pregnant during the study period, or of childbearing years and is unwilling to use and accepted form of birth control.

28. Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.

29. Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self- assessments is compromised (e.g. homeless, developmentally disabled and prisoner).

30. Is a relative of or an employee of the investigator or the clinical study site.

31. Has psychiatric or cognitive disorder and/or behavioural problems which in the opinion of the clinician may interfere with the study.

32. Has previously used the gammaCore® device.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ElectroCore INC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hans-Christoph Diener, Professor

Role: PRINCIPAL_INVESTIGATOR

Universtätsklinikum Essen

Locations

Neurology Department, University of Liège

Liège, , Belgium

Danish Headache Center

Glostrup Municipality, , Denmark

Neurologische Klinik und Poliklinik, Charité Campus Mitte

Berlin, , Germany

Klinik für Neurologie, Universitätsklinikum Essen

Essen, , Germany

CTC, University Medical Center Hamburg-Eppendorf

Hamburg, , Germany

Migräne- und Kopfschmertzklinik Königstein

Königstein, , Germany

Klinik für Neurologie, Ludwig-Maximilliams-Universität, Klinikum Grosshadern

München, , Germany

Zentrum für Neurologie und Epileptologie, Hertie-Institut für Klinische Hirnforschung

Tübingen, , Germany

DKD HELIOS Klinik Wiesbaden

Wiesbaden, , Germany

Neurology Department, Athens Naval Hospital

Athens, , Greece

Neurology Department, Leiden University Center

Leiden, , Netherlands

Sandvika Nevrosenter AS

Sandvika, , Norway

Headache Unit, University Hospital Vall d'Hebron

Barcelona, , Spain

Servicio de Neurologia, Hospital Ruber Internacional

Madrid, , Spain

Servicio de Neurologia, Clinica Universidad de Navarra

Pamplona, , Spain

Servicio de Neurologia, Hospital Clinico Universitario de Valencia

Valencia, , Spain

Basildon University Hospital

Basildon, Essex, United Kingdom

School of Clinical and Expermental Medicine

Birmingham, , United Kingdom

Neurology Department, The Southern Hospital

Glasgow, , United Kingdom

Neurology Department, Hull Royal Infirmary

Hull, , United Kingdom

Neurology Department, The Walton Center

Liverpool, , United Kingdom

Neurology Department, King's College London

London, , United Kingdom

Countries

Belgium; Denmark; Germany; Greece; Netherlands; Norway; Spain; United Kingdom

References

Diener HC, Goadsby PJ, Ashina M, Al-Karagholi MA, Sinclair A, Mitsikostas D, Magis D, Pozo-Rosich P, Irimia Sieira P, Lainez MJ, Gaul C, Silver N, Hoffmann J, Marin J, Liebler E, Ferrari MD. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia. 2019 Oct;39(12):1475-1487. doi: 10.1177/0333102419876920. Epub 2019 Sep 15.

Reference Type: DERIVED

PMID: 31522546 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

GM-11

Identifier Type: -

Identifier Source: org_study_id